Dr. Vlad Coric’s leadership as CEO of Biohaven is characterized by his unwavering commitment to underserved patients, relentless pursuit of a bold scientific vision, and an unparalleled drive to innovate and create value. Dr. Coric navigated Biohaven’s landmark FDA approvals for its migraine drugs, Nurtec® ODT and Zavzpret™ Intranasal, and spearheaded the acquisition of Biohaven’s CGRP portfolio by Pfizer in May 2022 for approximately $13 billion in total consideration.

Under Dr. Coric’s stewardship, Biohaven operates with urgency and intention in applying cutting-edge science to advance an innovative therapeutic portfolio of programs, spanning from early to late-stage clinical development. The company is advancing a broad portfolio of product candidates, primarily focused on neuroscience, immunology and oncology across five proprietary platforms for a range of rare and common diseases with high unmet medical needs.

Dr. Coric has over 20 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb prior to leading Biohaven. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. During his career, he has been involved in multiple drug development programs, including marketed drugs or filed NDAs such as Nurtec® ODT (rimegepant; oral calcitonin gene-related peptide antagonist), Zavzpret™ (zavegepant; intranasal calcitonin gene-related peptide antagonist), Abilify® (aripiprazole; partial dopamine agonist), Opdivo® (nivolumab; anti-PD1), Yervoy® (Ipilimumab; anti-CTLA-4), Daklinza® (daclatasvir; NS5A inhibitor) and Sunvepra® (asunaprevir; NS3 inhibitor).

Since July 2001, Dr. Coric has served as an Associate Clinical Professor of Psychiatry at Yale School of Medicine. He previously served as the inpatient chief of the Yale Clinical Neuroscience Research Unit and director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as president of the Connecticut Psychiatric Society and authored more than 70 peer-reviewed publications. Dr. Coric completed his internship at Yale-New Haven Hospital, residency training at the Yale Psychiatry Residency Training Program and fellowship at the Yale Division of Law and Psychiatry. Dr. Coric also served as the program-wide chief resident for the Yale Department of Psychiatry, and chief resident on the PTSD service at the West-Haven Connecticut Veterans Administration Hospital.

Dr. Coric earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree. He was named one of Connecticut’s Top 25 Healthcare Technology Leaders for 2022 and 2023 by The Healthcare Technology Report, listed in PharmaVoice 100 Standout Executives in 2023, and recognized as the EY Entrepreneur of the Year® 2018 Award in the New York region.